Skip to Main Content

Paper Details

Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Clin Cancer Res
35
2018
-, CEP85L, CNS tumors, Cancer, Chromosome 6q22 Microdeletions, GOPC, Glioma, Gliomas, Oncogenes, ROS1, ROS1 Fusions, ROS1 fusion, ROS1 fusion-positive glioblastoma cell, ROS1 fusions, ROS1-fusions, astrocytic lineage, brain cancer, cancer, cancer hotspot, cell-based model systems, ependymoma, glioblastoma, intrachromosomal 6q22, kinase genes, lorlatinib, malignancies, murine, patients, primary, primary brain cancer, primary central nervous system (CNS) tumors, primary central nervous system tumors, primary glioma, transforming oncogenes, tumor
Author NameAffiliation
Monika A DavarePape Pediatric Research Institute, Oregon Health and Sciences University
Monika A DavarePape Pediatric Research Institute, Oregon Health and Sciences University
Anupriya AgarwalKnight Cancer Institute, Oregon Health and Sciences University
Jacob P WagnerKnight Cancer Institute, Oregon Health and Sciences University
Sudarshan IyerPape Pediatric Research Institute, Oregon Health and Sciences University
Erwin G Van MeirSchool of Medicine and Winship Cancer Institute Emory University
Erwin G Van MeirSchool of Medicine and Winship Cancer Institute Emory University
Marc LadanyiMemorial Sloan Kettering Cancer Center
Brian J DrukerKnight Cancer Institute, Oregon Health and Sciences University
Brian J DrukerHoward Hughes Medical Institute
  • 1 - 10

Datasets

Release 1.2